Koichi Handa

Dr. Koichi Handa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
TMTatsuru Matsuo
Tatsuru Matsuo
HMHideaki Mamada
Hideaki Mamada
TMTakahisa Motomura
Takahisa Motomura
MMMayumi Matsushita
Mayumi Matsushita
KHKoichi Handa
Koichi Handa
Pharmacokinetic research plays an important role in the development of new drugs. Accurate predictions of human pharmacokinetic parameters are essential for the success of clinical trials. Clearance (CL) and volume of distribution (Vd) are important factors for evaluating pharmacokinetic properties, and many previous studies have attempted to use computational methods to extrapolate these values from nonclinical laboratory animal models to human subjects. However, it is difficult to obtain sufficient, comprehensive experimental data from these animal models, and many studies are missing critical values. This means that studies using nonclinical data as explanatory variables can only apply a small number of compounds to their model training. In this study, we perform missing-value imputation and feature selection on nonclinical data to increase the number of training compounds and nonclinical datasets available for these kinds of studies. We could obtain novel models for total body clearance (CLtot) and steady-state Vd (Vdss) (CLtot: geometric mean fold error [GMFE], 1.92; percentage within 2-fold error, 66.5%; Vdss: GMFE, 1.64; percentage within 2-fold error, 71.1%). These accuracies were comparable to the conventional animal scale-up models. Then, this method differs from animal scale-up methods because it does not require animal experiments, which continue to become more strictly regulated as time passes.

1 April 2021 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
TMTatsuru Matsuo
Tatsuru Matsuo
HMHideaki Mamada
Hideaki Mamada
TMTakahisa Motomura
Takahisa Motomura
MMMayumi Matsushita
Mayumi Matsushita
KHKoichi Handa
Koichi Handa
Research into pharmacokinetics plays an important role in the development process of new drugs. Accurately predicting human pharmacokinetic parameters from preclinical data can increase the success rate of clinical trials. Since clearance (CL) which indicates the capacity of the entire body to process a drug is one of the most important parameters, many methods have been developed. However, there are still rooms to be improved for practical use in drug discovery research; "improving CL prediction accuracy" and "understanding the chemical structure of compounds in terms of pharmacokinetics". To improve those, this research proposes a multimodal learning method based on deep learning that takes not only the chemical structure of a drug but also rat CL as inputs. Good results were obtained compared with the conventional animal scale-up method; the geometric mean fold error was 2.68 and the proportion of compounds with prediction errors of 2-fold or less was 48.5%. Furthermore, it was found to be possible to infer the partial structure useful for CL prediction by a structure contributing factor inference method. The validity of these results of structural interpretation of metabolic stability was confirmed by chemists.

25 April 2023 in Molecular Pharmaceutics
Verified
Journal Article
Open access
KHKoichi Handa
Koichi Handa
PWPeter Wright
Peter Wright
SYSaki Yoshimura
Saki Yoshimura
MKMichiharu Kageyama
Michiharu Kageyama
TITakeshi Iijima
Takeshi Iijima
ABAndreas Bender
Andreas Bender
Pharmacokinetic (PK) parameters such as clearance (CL) and volume of distribution (Vd) have been the subject of previous in silico predictive models. However, having information of the concentration over time profile explicitly can provide additional value like time above MIC or AUC, etc., to understand both the efficacy and safety-related aspects of a compound. In this work, we developed machine learning models for plasma concentration-time profiles after both i.v. and p.o. dosing for a series of 17 in-house projects. For explanatory variables, MACCS Keys chemical descriptors as well as in silico and experimental in vitro PK parameters were used. The predictive accuracy of random forest (RF), message passing neural network, 2-compartment models using estimated CL and Vdss, and an average model (as a control experiment) was investigated using 5-fold cross-validation (5-fold CV) and leave-one-project-out validation (LOPO-V). The predictive accuracy of RF in 5-fold CV for i.v. and p.o. plasma concentration-time profiles was the best among the models studied, with an RMSE for i.v. dosing at 0.08, 1, and 8 h of 0.245, 0.474, and 0.462, respectively, and an RMSE for p.o. dosing at 0.25, 1, and 8 h of 0.500, 0.612, and 0.509, respectively. Furthermore, by investigating the importance of the in vitro PK parameters using the Gini index, we observed that the general prior knowledge in ADME research was reflected well in the respective feature importance of in vitro parameters such as predicted human Vd (hVd) for the initial distribution, mouse intrinsic CL and unbound fraction of mouse plasma for the elimination process, and Caco2 permeability for the absorption process. Also, this model is the first model that can predict twin peaks in the concentration-time profile much better than a baseline compartment model. Because of its combination of sufficient accuracy and speed of prediction, we found the model to be fit-for-purpose for practical lead optimization.

21 November 2023 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
KHKoichi Handa
Koichi Handa
MTMorgan C. Thomas
Morgan C. Thomas
MKMichiharu Kageyama
Michiharu Kageyama
TITakeshi Iijima
Takeshi Iijima
ABAndreas Bender
Andreas Bender
While a multitude of deep generative models have recently emerged there exists no best practice for their practically relevant validation. On the one hand, novel de novo-generated molecules cannot be refuted by retrospective validation (so that this type of validation is biased); but on the other hand prospective validation is expensive and then often biased by the human selection process. In this case study, we frame retrospective validation as the ability to mimic human drug design, by answering the following question: Can a generative model trained on early-stage project compounds generate middle/late-stage compounds de novo? To this end, we used experimental data that contains the elapsed time of a synthetic expansion following hit identification from five public (where the time series was pre-processed to better reflect realistic synthetic expansions) and six in-house project datasets, and used REINVENT as a widely adopted RNN-based generative model. After splitting the dataset and training REINVENT on early-stage compounds, we found that rediscovery of middle/late-stage compounds was much higher in public projects (at 1.60%, 0.64%, and 0.21% of the top 100, 500, and 5000 scored generated compounds) than in in-house projects (where the values were 0.00%, 0.03%, and 0.04%, respectively). Similarly, average single nearest neighbour similarity between early- and middle/late-stage compounds in public projects was higher between active compounds than inactive compounds; however, for in-house projects the converse was true, which makes rediscovery (if so desired) more difficult. We hence show that the generative model recovers very few middle/late-stage compounds from real-world drug discovery projects, highlighting the fundamental difference between purely algorithmic design and drug discovery as a real-world process. Evaluating de novo compound design approaches appears, based on the current study, difficult or even impossible to do retrospectively.Scientific Contribution This contribution hence illustrates aspects of evaluating the performance of generative models in a real-world setting which have not been extensively described previously and which hopefully contribute to their further future development.

7 August 2026 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
ABAndreas Bender
Andreas Bender
MTMorgan C. Thomas
Morgan C. Thomas
JSJack W. Scannell
Jack W. Scannell
DSDavid A. Shaywitz
David A. Shaywitz
GGGian Marco Ghiandoni
Gian Marco Ghiandoni
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
Artificial intelligence (AI) in drug discovery has attracted increasing interest over the past decade. It is now time for a critical review of progress in the field: where did we advance — and where are we yet to see impact — when it comes to what matters in drug discovery, which is to deliver safer and more efficacious medicines to patients faster? Although a wide variety of AI methods have been developed, applied and benchmarked, evidence of their clinically relevant impact is, so far, disappointingly limited. In this Perspective we discuss potential reasons, including an insufficient focus on clinical translation during model development, difficulties with applying AI algorithms on conditional life science data, and insufficient problem definitions and the resulting underspecification of computational models for real-world use cases. ‘Technology push’ compared with ‘science pull’ is also likely to be an underlying factor, as well as the substantial time required to operationalize technical capabilities into systems that are sufficiently scaled and accessible for users. We provide recommendations for the development of AI in drug discovery with the aim of increasing its translational relevance. For example, benchmarking studies of AI tools in drug discovery need to move on from model validation and instead focus on their ability to improve decision making.

2 June 2023 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
KHKoichi Handa
Koichi Handa
SSSeishiro Sakamoto
Seishiro Sakamoto
MKMichiharu Kageyama
Michiharu Kageyama
TITakeshi Iijima
Takeshi Iijima